Furthermore, MTX-13, another PTK7-targeting ADC carrying the topoisomerase I inhibitor exatecan, demonstrated sustained tumor regressions across a broader range of PTK7-positive tumors, suggesting its expanded therapeutic potential [52]. Here, PTK7 is linked to neoplasm.